Across TCGA pan-cancer cohorts, CSF2RA Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CSF2RA data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in small cell lung cancer (SCLC), where higher CSF2RA Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CSF2RA expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
SCLC, ACC, and UCEC are the cancer types where CSF2RA Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.